Data show that Angiomax (bivalirudin) provides acute coronary syndrome patients who are undergoing PCI with similar results from ischaemic events and death versus standard therapy.
The FAME trial showed that routine measurements of fractional flow reserve during percutaneous coronary intervention compared to angiographic approach reduces rate of composite endpoint of death.
In JUPITER (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin), a clinical trial enrolling individuals who do not currently qualify for statin therapy, rosuvastatin significantly reduced all-cause mortality by 20%.
The aim of this article is to review the incidence and all the possible causes and consequences of a suboptimal stent expansion.
Professor Alain Cribier is a pioneer in the field of aortic and mitral valvulopl...
Professor Fausto Pinto discusses his major influences, his career achievements and his passion for travelling, books and music.
The Editor of Vascular News, Professor Roger Greenhalgh, Imperial College, London, writes a personal appreciation of DeBakey.
0
A market report from BIBA Research shows that drug-eluting stents (DES) penetration rate in Western and Central Europe increased by 1.1% to 47.6% in the second quarter 2008.
